一种纳米碳激活的混合化策略,用于构建药理学合作疗法,以增强抗癌疗效
Huan Wang1, Xinchen Liu2, Xiangyu Yan3
1State Key Laboratory of Rare Earth Resources Utilization and Laboratory of Chemical Biology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun Jilin 130022 P. R. China jren@ciac.ac.cn xqu@ciac.ac.cn.
研究人员通过将碳量子点与抗氧化剂抑制剂和协核化前体结合,开发了新型纳米药物. 这些纳米药物显示出增强的抗癌能力和改善的治疗疗效 in vivo.
科学领域:
- 纳米医学是一种纳米医学.
- 药用化学 医学化学
- 材料科学 材料科学 材料科学
背景情况:
- 药物设计原则对于开发有效的纳米药物至关重要.
- 药杂化和纳米碳合成为新药开发提供了战略.
- 开发合作纳米药物可以提高癌症治疗的治疗结果.
研究的目的:
- 为构建药理学上合作的纳米药物提出一个纳米碳支持的混合化策略.
- 通过混合抗氧化剂抑制剂和使用碳量子点的共同核化前体来设计纳米药物 (SCACD).
- 评估这些新型纳米药物用于癌症治疗的增强生物活性和体内疗效.
主要方法:
- 通过碳量子点形成,抗氧化剂防御药理抑制剂和共核化前体的结构混合.
- 基于药用碳核的带结构评估声触媒活性.
- 在黑色素瘤模型中评估抗氧化剂防御抑制活性和体内疗效.
主要成果:
- 开发的纳米药物 (SCACD) 显示出卓越的声催化活性.
- 与原始抑制剂相比,SCACDs的抗氧化防御抑制活性超过十倍.
- 活体研究表明,在低剂量下,长时间保留体内,可取的生物分布和有效消除黑色素瘤细胞.
结论:
- 纳米碳启用混合化策略是有效的制造药理学合作纳米药物.
- SCACDs具有双重增强的生物活性,从而提高了治疗疗效.
- 这种方法为开发用于癌症治疗的先进纳米药物提供了可行的途径.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
